Candel Net Income From Continuing Ops from 2010 to 2026
| CADL Stock | USD 5.84 0.09 1.52% |
Net Loss | First Reported 2020-06-30 | Previous Quarter -4.8 M | Current Value -11.3 M | Quarterly Volatility 6.6 M |
Check Candel Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Candel Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 1.2 M, Depreciation And Amortization of 1.2 M or Interest Expense of 2.5 M, as well as many indicators such as Price To Sales Ratio of 451, Dividend Yield of 0.0 or PTB Ratio of 3.92. Candel financial statements analysis is a perfect complement when working with Candel Therapeutics Valuation or Volatility modules.
Candel | Net Income From Continuing Ops | Build AI portfolio with Candel Stock |
Historical Net Income From Continuing Ops data for Candel Therapeutics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Candel Therapeutics represents a compelling investment opportunity.
Latest Candel Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Candel Therapeutics over the last few years. It is Candel Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Candel Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Candel Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (19,937,508) | |
| Coefficient Of Variation | (85.48) | |
| Mean Deviation | 14,161,894 | |
| Median | (8,240,000) | |
| Standard Deviation | 17,043,385 | |
| Sample Variance | 290.5T | |
| Range | 46.9M | |
| R-Value | (0.83) | |
| Mean Square Error | 95.2T | |
| R-Squared | 0.69 | |
| Significance | 0.000034 | |
| Slope | (2,809,389) | |
| Total Sum of Squares | 4647.6T |
Candel Net Income From Continuing Ops History
About Candel Therapeutics Financial Statements
Candel Therapeutics investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Candel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -49.7 M | -47.2 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Candel Therapeutics Correlation against competitors. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. Projected growth potential of Candel fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Candel Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Candel Therapeutics requires distinguishing between market price and book value, where the latter reflects Candel's accounting equity. The concept of intrinsic value—what Candel Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Candel Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Candel Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Candel Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Candel Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.